![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Merck Serono and Domain Therapeutics Announce an Agreement to Develop Drugs for Parkinson's Disease - Merck Serono to Develop Domain Therapeutics' mGluR4 Allosteric Modulators PR Newswire GENEVA...
Brighter Futures in MS - Inspiring Short Film Premieres in Brussels PR Newswire GENEVA and BRUSSELS, January 12, 2011 GENEVA and BRUSSELS, January 12, 2011 /PRNewswire/ -- Merck Serono, a...
Merck Serono and San Raffaele Scientific Institute to Collaborate on Research in Neurodegenerative Diseases PR Newswire GENEVA, December 13, 2010 GENEVA, December 13, 2010 /PRNewswire/ -- Merck...
Merck Serono Announces Extension of FDA Priority Review Period for Cladribine Tablets for the Treatment of Relapsing Forms of Multiple Sclerosis - FDA Extends Priority Review period of Cladribine...
Merck Serono: Enrollment Completed for ORACLE MS Study of Cladribine Tablets in Patients at Risk of Developing MS PR Newswire GENEVA, November 17, 2010 GENEVA, November 17, 2010 /PRNewswire/...
Merck Serono: Ready-to-Use Formulation of Recombinant Growth Hormone Saizen Recommended for Approval in Europe - Saizen(R) Solution For Injection Eliminates the Need to Reconstitute Powder for...
Merck Serono Announces Top-Line Results of Long-Term Study of Safinamide as Add-on Treatment to Levodopa in Advanced Parkinson's Disease PR Newswire GENEVA, Switzerland, November 4, 2010 GENEVA...
Merck Serono Sells Théramex to Teva for EUR 265 Million - Acquisition Will Provide Teva With a Strong Platform to Expand its Global Women's Health Business - Merck Serono to Maintain Focus on its...
Merck Serono: REFLEX Study Results Show Treatment With Rebif(R) Delays Conversion to MS in Patients With First Clinical Signs of the Disease - Study Met its Primary Endpoint - Risk of Converting...
Merck Serono to Introduce RebiDose(TM), the Rebif(R) Single Use Pre-filled Pen for Treatment of Multiple Sclerosis - RebiDose(TM) has Been Developed With the Goal to Simplify the Rebif(R...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions